Results 211 to 220 of about 315,013 (309)

Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
Are two drugs better than one in advanced NSCLC? ABSTRACT Background Randomized studies have demonstrated superior overall survival (OS) of pembrolizumab (pembro), both alone and in combination with chemotherapy (chemo) over chemo alone in patients with programmed cell death ligand‐1 (PD‐L1) ≥ 50% advanced non–small cell lung cancer (NSCLC).
Junipearl Cheng   +5 more
wiley   +1 more source

IgG4‐Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets

open access: yesAllergy, EarlyView.
ABSTRACT IgG4, the least abundant IgG subclass in humans, is increasingly recognised for its involvement in allergic and autoimmune pathologies. Its unique properties, such as the tendency to form half‐molecules (one heavy chain and one light chain) and its generally non‐inflammatory nature, distinguish it from other IgG subclasses.
Louisa Tedesco   +8 more
wiley   +1 more source

Does out of Hours Endoscopic Retrograde Cholangiopancreatography Lead to Higher Pancreatitis and Hospitalization Rates?

open access: yesANZ Journal of Surgery, EarlyView.
The aim of this study was to determine if ERCP related morbidity is higher if performed out of workinghours. Contemporaneously collected data patients undergoing ERCP at an Australian hospital were analysed. No difference was found in rates of post‐ERCP pancreatitis (PEP) in patients undergoing out of hours ERCP compared with in hours ERCP (p = 0.759).
Hasib Ahmadzai   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy